MGX · ISSUER CIK 1785279
Metagenomi Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 4 Metagenomi Therapeutics, Inc. insiders reported $23K of open-market purchases and $5K of sales on SEC Form 4. The largest buyer was Reid Laurence (Director), with $23K.
↗4 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 0 of 3 sales were reported under a 10b5-1 plan.
$23KInsider buying
$5KInsider selling
+$18KNet open-market
Sep 11, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 11, 202619:51 | Sep 9, 2026 | MGX | Director | P · Buy | $1.17 | +20,000 | 20,000 | New | +$23K | -11.4% | -29.1% |
| Sep 10, 202615:47 | Sep 8, 2026 | MGX | See Remarks | S · Sell | $1.16 | −358 | 126,133 | -0% | −$414.71 | ||
| Sep 10, 202615:40 | Sep 8, 2026 | MGX | See Remarks, Director | S · Sell | $1.16 | −2,140 | 375,393 | -1% | −$2K | ||
| Sep 10, 202615:34 | Sep 8, 2026 | MGX | Chief Financial Officer | S · Sell | $1.16 | −1,911 | 206,580 | -1% | −$2K |